Top Page
Lumos Diagnostics Holdings Ltd.
(Sydney:LDX)
Lumos Diagnostics Holdings Ltd. (LDX) vs. iShares MSCI Australia ETF (EWA)
Lumos Diagnostics Holdings Ltd. Business Overview & Revenue Model
Lumos Diagnostics Holdings Ltd. Earnings Call Summary
Lumos Diagnostics Holdings Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.40M | 12.50M | 11.13M | 10.54M | 11.63M | 18.85M |
| Gross Profit | 7.68M | 7.91M | 7.10M | 5.32M | 4.46M | 8.60M |
| EBITDA | -6.08M | -4.63M | -5.44M | -4.93M | -25.67M | -10.69M |
| Net Income | -7.18M | -7.18M | -8.59M | -8.97M | -45.72M | -15.03M |
Balance Sheet | ||||||
| Total Assets | 20.81M | 20.81M | 26.84M | 25.42M | 36.94M | 97.99M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 1.96M | 6.48M | 3.02M | 7.98M | 44.89M |
| Total Debt | 6.99M | 6.99M | 8.06M | 9.79M | 7.19M | 7.96M |
| Total Liabilities | 14.65M | 14.65M | 19.73M | 15.92M | 19.05M | 39.71M |
| Stockholders Equity | 6.16M | 6.16M | 7.11M | 9.50M | 17.89M | 58.28M |
Cash Flow | ||||||
| Free Cash Flow | -9.39M | -9.39M | 848.00K | -9.79M | -22.39M | -16.77M |
| Operating Cash Flow | -9.33M | -9.33M | 946.00K | -9.64M | -18.04M | -10.89M |
| Investing Cash Flow | -53.00K | -53.00K | -98.00K | 4.31M | -4.36M | -8.33M |
| Financing Cash Flow | 5.28M | 5.28M | 2.63M | 652.00K | -10.92M | 63.27M |
Lumos Diagnostics Holdings Ltd. Technical Analysis
Lumos Diagnostics Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$54.81M | -2.94 | -40.54% | ― | 29.60% | 33.00% | |
46 Neutral | AU$225.85M | -16.15 | -111.23% | ― | 12.96% | 40.81% | |
45 Neutral | AU$47.85M | -6.31 | -97.79% | ― | ― | 23.85% | |
44 Neutral | AU$53.96M | -11.63 | -501.54% | ― | ― | 56.42% | |
41 Neutral | AU$52.24M | -2.43 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$54.90M | -6.18 | -37.78% | ― | 2.33% | 12.50% |
Lumos Diagnostics Holdings Ltd. Corporate Events
Lumos Diagnostics has secured a follow-on contract with New Jersey-based Aptatek Biosciences to manage an Institutional Review Board-approved multi-centre clinical study aimed at obtaining US Food and Drug Administration clearance for PheCheck, an aptamer-based in-home monitoring device for phenylketonuria (PKU). Valued at about US$0.4 million and scheduled to begin in the second quarter of calendar 2026 for roughly six months, the contract expands Lumos’s role beyond product development into full clinical and regulatory support, including study management, data analysis and preparation of the clinical report for FDA submission, and runs in parallel with ongoing product development and verification work; successful clearance could position Lumos for further revenue from test and reader manufacturing, strengthening its presence in the high-value rare disease diagnostics segment as PheCheck, which already holds FDA Breakthrough Device designation, targets a critical unmet need in at-home PKU monitoring.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics has issued a total of 5,228,863 new fully paid ordinary shares following the exercise of unquoted options by Lind Global Fund II and a company employee, with the shares issued without a prospectus under relevant Corporations Act provisions. In a cleansing notice to the market, the company confirmed it remains compliant with its continuous disclosure and financial reporting obligations, stated there is no excluded information that must be disclosed ahead of its FY 2026 half-year report due by 27 February 2026, and indicated that the expected draft of that report does not contain undisclosed price-sensitive information, helping to maintain regulatory transparency for investors as its capital base modestly expands.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics Holdings Ltd. has applied to the ASX for quotation of 5,228,863 new ordinary fully paid shares, to be traded under its existing ticker LDX. The issuance of these additional securities, arising from the exercise or conversion of existing instruments, modestly expands the company’s listed share capital and may enhance liquidity for investors while signalling ongoing capital management activity.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics is hosting an investor and shareholder webinar titled “Reducing Diagnostic Uncertainty” to showcase how its FebriDx rapid diagnostic test supports evidence-based antibiotic stewardship in outpatient and urgent care settings, particularly during the busy cold and flu season. The session will feature real-world insights from WellStreet Urgent Care, where FebriDx has been integrated into high-volume workflows to improve diagnostic clarity, strengthen stewardship practices, and enhance clinical efficiency, underlining the test’s growing clinical adoption and highlighting Lumos’ positioning in the point-of-care diagnostics market; a recording will be available to all registered participants after the event.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics has entered into a distribution partnership with Interlux Group to expand the availability of its FebriDx® point-of-care diagnostic test in the Baltic region, covering Lithuania, Estonia, and Latvia. This collaboration strengthens Lumos’ presence in Europe, aligning with its strategy to broaden the reach of FebriDx® through established regional partners and enabling quicker adoption in primary care and other healthcare settings.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
Lumos Diagnostics Holdings Ltd has issued 35,341 fully paid ordinary shares following the exercise of 42,000 unquoted options by its employees. This issuance was conducted without disclosure under the Corporations Act, and the company confirms its compliance with relevant statutory provisions, indicating a transparent and regulated approach to its operational activities.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 35,341 fully paid ordinary securities on the ASX, following the exercise of options or conversion of other convertible securities. This move is part of the company’s ongoing efforts to enhance its financial flexibility and strengthen its market position, potentially impacting its operational capabilities and offering growth opportunities for stakeholders.
Lumos Diagnostics has achieved full U.S. Medicare reimbursement recognition for its FebriDx® test, securing approval from all seven Medicare Administrative Contractors (MACs), including the final approval from National Government Services. This development ensures FebriDx is positioned for broad adoption across the U.S. healthcare system, facilitating access through Medicare Advantage, Medicaid, and private payors. The company will now focus on assisting MACs in developing written policies to streamline reimbursement claims, enhancing clarity and predictability for stakeholders.
Lumos Diagnostics Holdings Ltd. has announced the issuance of 6,007,000 performance rights as part of an employee incentive scheme. This move is aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially impacting the company’s operational dynamics and stakeholder interests positively.
Lumos Diagnostics Holdings Ltd. has announced the quotation of 1,323,875 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 31, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially expand its market presence, impacting its operations and positioning within the healthcare diagnostics industry.
Lumos Diagnostics Holdings Ltd has announced a change in the director’s interest, with Doug Ward acquiring 22,000,000 performance rights. This change, approved by shareholders at the company’s 2025 Annual General Meeting, reflects a strategic move to align the interests of the director with the company’s growth objectives, potentially impacting the company’s operations and stakeholder interests.
Lumos Diagnostics Holdings Ltd. announced the issuance of 22 million unquoted performance rights as part of an employee incentive scheme. This move is likely to enhance employee engagement and align their interests with the company’s growth objectives, potentially impacting its operational efficiency and market positioning.
Lumos Diagnostics has announced the adoption of a revised Constitution, as approved by shareholders at their 2025 Annual General Meeting. This update is part of the company’s ongoing efforts to align its governance framework with current operational and strategic needs, potentially impacting its operational efficiency and stakeholder engagement.
Lumos Diagnostics Holdings Ltd. announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of a director, approval of performance rights, and ratification of share issues. These outcomes reflect strong shareholder support and are expected to positively impact the company’s governance and strategic initiatives.
Lumos Diagnostics Holdings Ltd. recently held its Annual General Meeting, where the CEO presented key updates about the company’s operations and strategic direction. The presentation emphasized the company’s commitment to advancing its diagnostic solutions and highlighted the challenges and opportunities in the market. While the document provided valuable insights into Lumos’ market positioning and future plans, it also contained disclaimers about forward-looking statements, advising stakeholders to consider the inherent risks and uncertainties.
Lumos Diagnostics has made significant strides in FY25, transitioning from an early-stage business to an emerging global diagnostics company. The company has expanded its distribution partnerships, notably with Henry Schein and PHASE Scientific, and has secured reimbursement for FebriDx on the U.S. Medicare fee schedule. A successful CLIA waiver trial for FebriDx has been completed, with the application submitted to the FDA, potentially expanding the U.S. market significantly. A new distribution agreement with PHASE Scientific could be worth up to US$317 million, marking a major milestone for Lumos. The company remains well-funded, with a focus on disciplined execution and expanding its product’s clinical use, supported by BARDA.
Lumos Diagnostics reported a steady revenue of US$3.4 million for the first quarter of FY26, with a notable 300% increase in product revenue driven by the adoption of FebriDx® in the U.S. The company secured a significant distribution agreement with PHASE Scientific and is awaiting feedback on a CLIA waiver submission for FebriDx. Lumos also continues its development projects, including an expanded agreement with Hologic for a next-generation diagnostic product, and has secured a loan facility to support its working capital needs.
Lumos Diagnostics Holdings Ltd has initiated a pediatric study for its FebriDx® device in the United States, targeting children aged 2 to 12 years. This study, supported by BARDA with significant funding, aims to expand the device’s usage to differentiate bacterial from non-bacterial acute respiratory infections in younger children, potentially increasing Lumos’ market reach significantly if successful.